Context
Sensorion is a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss.
The company develops two novel gene therapy programs targeting unmet needs in Usher Syndrome Type 1 and Otoferlin Deficiency, with promising preclinical data.
The company has established exclusive collaboration with Institut Pasteur for all Inner Ear Gene Therapy Programs.
Sensorion’s oral small molecule candidate SENS-401, and most advanced clinical project, is expected to deliver Phase 2 results in Sudden Sensorineural Hearing Loss by mid-2021.
Follow-on Offering proceeds will be mainly used to develop the company’s current gene therapy programs (OTOF and USHER), potentially broaden the gene therapy pipeline, support pharmacology and clinical studies for phase 3 development of SENS-401, working capital and general corporate purposes.
About Sensorion
Sensorion is a pioneering clinical-stage biotech company, which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders. Its clinical-stage portfolio includes one Phase 2 product: SENS- 401 (Arazasetron) for sudden sensorineural hearing loss (SSNHL). Sensorion has built a unique R&D technology platform to expand its understanding of the pathophysiology and etiology of inner ear related diseases enabling it to select the best targets and modalities for drug candidates. The company is also working on the identification of biomarkers to improve diagnosis of these underserved illnesses. In the second half of 2019, Sensorion launched two preclinical gene therapy programs aiming at correcting hereditary monogenic forms of deafness including Usher Type 1 and deafness caused by a mutation of the gene encoding for Otoferlin. The company is uniquely placed, through its platforms and pipeline of potential therapeutics, to make a lasting positive impact on hundreds of thousands of people with inner ear related disorders, a significant global unmet medical need.
Deal Team
Should you want to know more about this transaction, you can contact one of the team members above
Bryan, Garnier & Co acts as Joint Bookrunner on Sensorion’s EUR 31 million Follow-on Offering with top tier US and European biotech specialists and institutional investors
Bryan, Garnier & Co acted as Joint Bookrunner on Sensorion’s EUR 31m Follow-on Offering, which closed on 18 September.
In a wall-crossed overnight ABB, Sensorion raised EUR 31m from Tier-1 US and European healthcare specialists, anchored by high-profile biotech investors, including Invus and Sofinnova, the company’s main shareholders.
The transaction was priced at EUR 1.70 a share, representing a discount of 6.3% to the last market closing price (17 September 2020).
This is another landmark transaction for Bryan, Garnier & Co, which demonstrates its unique ability to raise capital for European gene therapy biotech companies in a highly competitive fundraising environment.
Share